FibroGen: Data from Phase 3 Trial of Roxadustat in Myelodysplastic Syndromes Linked Anemia

 A post hoc analysis of patients with higher transfusion burden at baseline showed a larger percentage of patients achieved transfusion independence ≥ 56 days with roxadustat vs. placebo (36.1% vs 11.5%; p=0.047ǂ).

Dr. Moshe Mittelman’s presentation was selected for the “2024 Highlights of ASH”

https://www.marketscreener.com/quote/stock/FIBROGEN-INC-18537026/news/FibroGen-Presents-Data-from-Phase-3-MATTERHORN-Trial-of-Roxadustat-in-Patients-with-Anemia-of-Lower-45537338/